Carl Zeiss Meditec AG (XSWX:AFX) FFO


XSWX:AFX Carl Zeiss Meditec AG XSWX:AFX
79 GF Score
Price CHF24.80
GF Value CHF67.74
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Carl Zeiss Meditec AG FFO?

FFO (Funds from operations) only applies to REITs.

XSWX:AFX
79GF Score
Carl Zeiss Meditec AG XSWX:AFX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Carl Zeiss Meditec AG (XSWX:AFX) Overvalued in 2026?

Based on GuruFocus' analysis, Carl Zeiss Meditec AG stock appears to be undervalued. The current stock price of CHF24.80 is trading 63.4% below its estimated GF Value™ of CHF67.74. GuruFocus considers Carl Zeiss Meditec AG to be Significantly Undervalued.

Key valuation signals for XSWX:AFX:

  • FFO:
  • GF Value™: CHF67.74 vs. price of CHF24.80 (63.4% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the XSWX:AFX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Carl Zeiss Meditec AG Business Description

Address Goschwitzer Strasse 51-52, Jena, TH, DEU, 07745
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world, and it operates in two segments: ophthalmic devices and microsurgery. OPT, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, as well as a portfolio of intraocular lenses and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. MCS is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% market share, Zeiss is the clear leader in the microsurgery space.
79GF Score

Get the complete analysis for XSWX:AFX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF24.80
Price
CHF67.74
GF Value